ABUS vs BILL · P/E 5.4, rev $6.2M vs rev $1.46B
Arbutus Biopharma Corp (ABUS) versus Bill Com Holdings Inc (BILL) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Bill Com Holdings Inc (BILL) is a software - application company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported BILL revenue for 2025-06-30 was $1.46B. Net income was $23.8M. Revenue was up 13.4% from 2024-06-30 to 2025-06-30. BILL currently screens at market cap $4.78B.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. BILL currently screens at market cap $4.78B.
Not investment advice. Open the ABUS and BILL stock pages for the full models.
Not investment advice.